In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—Celgene’s Otezla (2014), Novartis’s Cosentyx (2015), Eli Lilly’s Taltz (2016), Valeant’s Siliq (2017), Janssen’s Tremfya (2017), and Sun Pharma’s Ilumya (2018)—is anticipated to substantially alter the market landscape. The Psoriasis Emerging Therapy series includes three waves that will track the awareness, trial, and use of Tremfya following its launch in July 2017 for the treatment of psoriasis. In addition, the series will examine physicians’ anticipation of future trends in psoriasis treatment, particularly Tremfya’s uptake, and assess Janssen’s promotional efforts.

Questions Answered:

  • What is the awareness of, familiarity with, and perceptions related to Tremfya among U.S. dermatologists?
  • According to prescribers, to which patients are they prescribing Tremfya, why are they prescribing Tremfya, and how satisfied are they with Tremfya?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Tremfya tracking compared with other recent product launches in the autoimmune market?

Product Description:

Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Psoriasis - Emerging Therapies - Tremfya Launch Tracking Wave 3 (US)
    • Key Findings
      • Benchmarking Tremfya Launch Success vs. Other Launched Drugs
        • Prescriber and Nonprescriber Profiles
          • Differences Between Tremfya Prescribers and Nonprescribers
          • Differences Between Tremfya Prescriber and Nonprescriber Profiles
        • Tremfya Awareness and Perceptions
          • Unaided and Aided Awareness of Tremfya
            • Recent Changes Made to Psoriasis Treatment
            • Unaided Awareness of Approved Drugs for Psoriasis
            • Awareness of Tremfya
            • Awareness of Tremfya's Approved Label for Psoriasis
            • Awareness of Tremfya's Dosing
            • Estimated Cost of Tremfya
          • Familiarity with Tremfya
            • Sources of Familiarity with Tremfya
              • Initial Reaction to and Interest in Tremfya
                • Tremfya Product Profile
                • Initial Reaction to Tremfya After Viewing Product Profile
                • Initial Reaction to Tremfya After Viewing Product Profile: Mean
                • Initial Reaction to Key Attributes of Tremfya After Viewing Product Profile
                • Initial Reaction to Key Attributes of Tremfya After Viewing Product Profile: Mean
                • Interest in Learning More About Tremfya
                • Interest in Learning More About Tremfya: Mean
              • Impressions of Tremfya
                • Physician Awareness of Tremfya Drug Profile
                • Aspects of Tremfya Profile of Which Dermatologists Were Unaware
                • Perceived Uniqueness of Tremfya
                • Perceived Uniqueness of Tremfya: Mean
                • Risk-Benefit Ratio of Tremfya
                • Risk-Benefit Ratio of Tremfya: Mean
                • Unaided Advantages of Tremfya
                • Unaided Disadvantages of Tremfya
              • Prescriber and Nonprescriber Profiles
                • Differences Between Tremfya Prescriber and Nonprescriber Profiles
            • Tremfya Trial and Use
              • Willingness to Prescribe Tremfya
                • Willingness to Prescribe Tremfya to Psoriasis Patients
                • Willingness to Prescribe Tremfya to Psoriasis Patients: Mean
                • Impact of Attributes on Willingness to Prescribe Tremfya
                • Impact of Attributes on Willingness to Prescribe Tremfya: Mean
              • Number of Patients Currently Receiving Tremfya
                • Tremfya Patient Volume
                • Tremfya Patient Volume: Mean
                • Timing of Tremfya Prescription
                • Biologics and Novel Oral Agents Currently Prescribed to Psoriasis Patients
                • Disease Severity of Tremfya-Treated Patients
                • Agents to Which Patients Switched After Discontinuing Tremfya
                • Origination of Patients Treated with Tremfya
                • Agents from Which Patients Were Switched to Tremfya
                • Therapies to Which Tremfya Was Added
                • Reasons for Prescribing Tremfya
                • Number of Patient Inquiries for Tremfya
                • Number of Patient Inquiries for Tremfya: Mean
                • Results of Specific Patient Inquiries for Tremfya
              • Reasons for Not Yet Prescribing Tremfya
                • Anticipated Tremfya Use
                  • Nonprescriber Timeline for Tremfya Trial
                  • Anticipated New Tremfya Users in the Next Month
                  • Anticipated New Tremfya Users in the Next Month: Mean
                  • Candidates for Tremfya by Psoriasis Patient Population
                  • Candidates for Tremfya by Treatment History
                  • Therapies That Tremfya Is Likely to Replace
                  • Obstacles to Prescribing Tremfya
                  • Anticipated Prescribing of Biologics and Novel Oral Therapies
                • Tremfya Performance on Key Attributes
                  • Overall Satisfaction with Tremfya
                  • Reasons for High Overall Satisfaction with Tremfya
                  • Ease of Tremfya's Managed Care Approval Process
                  • Requirements for Tremfya's Managed Care Approval
                  • Mean Total Tremfya Performance on Key Attributes
                  • Mean Tremfya Performance on Key Attributes: Prescribers vs. Nonprescribers
                  • Tremfya Performance on Key Attributes: Prescribers vs. Nonprescribers
                  • Total Tremfya Performance on Key Attributes
              • Effectiveness of Face-to-Face Detailing for Tremfya
                • Tremfya Sales Representative Frequency and Reach
                  • Most Recent Contact with a Tremfya Representative
                  • Frequency of Tremfya Representative Visits to Surveyed Dermatologists
                  • Frequency of Tremfya Representative Visits to Surveyed Dermatologists: Mean
                • Satisfaction with Tremfya Sales Representative
                  • Performance of Tremfya Sales Representatives
                  • Performance of Tremfya Sales Representatives: Mean
                • Tremfya Message Recall
                  • Message Recall During Recent Detail
                  • Percentage of Physicians Who Received Ideal Tremfya Candidate Suggestion from Representative
                  • Ideal Tremfya Candidate Suggestions Made by Representative
                  • Materials Used During Tremfya Sales Representative Visit
                  • Agents Positioned Against Tremfya During Sales Representative Visit
              • Methodology
                • Primary Market Research Methodology
                • Physician Demographics
                  • U.S. State of Practice
                  • Years in Practice Post-Residency
                  • Number of Psoriasis Patients Under Physicians' Personal Management
                  • Number of Psoriasis Patients Currently Taking Biologics
                  • Percentage of Psoriasis Patients Currently Taking Biologics
                  • Percentage of Adult Psoriasis Patients
                  • Practice Location
                  • Practice Setting
                  • Geographic Distribution
              • Appendix
                • Additional Primary Market Research
                  • Anticipated New Tremfya Users in the Next Month: Mean
                  • Patients Treated, by Disease Severity
                  • Percentage of Patients Receiving Prescription Drug Therapy
                  • Percentage of Patients Receiving Prescription Drug Therapy by Treatment Category
                  • Percentage of Patients Receiving Phototherapy
                  • Timing of Tremfya Prescription
                  • Tremfya Discontinuation Rate
                  • Reasons for Discontinuing Tremfya
                  • Average Time Between Tremfya Initiation and Discontinuation
                  • Average Time Between Tremfya Initiation and Discontinuation: Mean
              • Abbreviations

            Author(s): Matthew W. Scutcher, MEng PhD; Yingdee Unhavaithaya

            Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.  

            In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry

            He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.

            Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis.

            Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials progression.  He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing opportunities.  Yingdee received his Ph.D. in cell biology from the University of Massachusetts Medical School, and a B.S. in biology from the University of Pittsburgh at Greensburg.


            Related Reports

            Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

            The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

            View Details

            Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

            Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management o...

            View Details

            Psoriasis | Disease Landscape and Forecast | G7 | 2020

            The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

            View Details

            Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

            Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

            View Details